Cardiovascular Disease in HIV-Infected Patients: Predict It and Prevent It
Source: Cardiovascular Disease in HIV-Infected Patients: Predict It and Prevent It

Interactive Virtual Presentation

In this interactive program, cardiologist Priscilla Y. Hsue, MD, and HIV specialist David A. Wohl, MD, share coordinating perspectives on using traditional, HIV-related, and inflammatory factors to predict and manage cardiovascular risk in HIV-infected patients.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Appropriately interpret data on cardiovascular disease markers in studies of HIV-infected patients
  • Assess cardiovascular disease risk in HIV-infected patients
  • Apply data on cardiovascular disease risk when selecting treatment for patients with HIV infection

Topics covered include:

  • Epidemiology
  • Risk Assessment
  • Inflammatory Markers and Imaging
  • Role of Antiretroviral Therapy
  • Statins
 

Faculty

  • Priscilla Y. Hsue
    MD
    David A. Wohl
    MD

Credit Information

  • Release Date:
    July 14, 2015
  • Expiration Date:
    July 13, 2016
  • Physicians:
    maximum of 1.0 AMA PRA Category 1 Credit

Information on this Educational Activity

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty

Priscilla Y. Hsue, MD


Professor of Medicine
University of California at San Francisco
San Francisco General Hospital
San Francisco, California

Priscilla Y. Hsue, MD, has disclosed that she has served on the advisory boards for Bristol-Myers Squibb, Gilead Sciences, and Merck and has received honoraria from Gilead Sciences.
 

David A. Wohl, MD


Associate Professor of Medicine
School of Medicine
Site Leader, AIDS Clinical Trials Unit-Chapel Hill
University of North Carolina at Chapel Hill
Director, North Carolina AIDS Training and Education Center
Chapel Hill, North Carolina
Co-Director for HIV Services
North Carolina Department of Correction
Raleigh, North Carolina

David A. Wohl, MD, has disclosed that he has received consulting fees from Gilead Sciences and Janssen and funds for research support from Gilead Sciences and Merck.
 

Staff

Jennifer M. Blanchette, PhD


Associate Managing Editor

Jennifer Blanchette, PhD, has no real or apparent conflicts of interest to report.
 

Jenny Schulz, PhD


Editorial Director, Virology & Other Therapeutic Areas

Jenny Schulz, PhD, has no real or apparent conflicts of interest to report.
 

Elaine P. Seeskin, 


Editorial Contributor

Elaine P. Seeskin has no real or apparent conflicts of interest to report.
 

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

 

Target Audience

This activity is intended for infectious disease physicians, HIV specialists, and other clinicians who care for patients with HIV infection.


Goal

The goal of this activity is to improve clinicians’ competence in both assessing CVD risk in patients with HIV and in considering the impact on patients’ CV risk profiles when selecting antiretroviral therapies for their patients with HIV infection.


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Appropriately interpret data on cardiovascular disease markers in studies of HIV-infected patients
  • Assess cardiovascular disease risk in HIV-infected patients
  • Apply data on cardiovascular disease risk when selecting treatment for patients with HIV infection
 

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Commercial Support


This program is supported by an educational grant from Bristol-Myers Squibb.

 

Program Medium


This program has been made available online.

 

Site Requirements


  • Internet Explorer 7+, Firefox 3+, Safari 3+, or Chrome
  • JavaScript enabled
  • 1024x768+ screen resolution
  • Adobe Flash Player
 

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 14, 2015, through July 13, 2016:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 70% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME activities completed can be found on the "CME Manager" page. There are no costs/fees for this activity.